We’re here to answer your questions about the RaDaR® test and help you have informed conversations with your healthcare team.


Our Patient Support Team is here to help

Phone: 866.776.5907, option 9

RaDaR is cutting-edge technology that can help determine if your cancer is still there after treatment

RaDaR – which stands for residual disease and recurrence – is a liquid biopsy (blood test) that can detect very small amounts of cancer that may still be present in your body after your treatment.

After treatment, if small amounts of tumor DNA are found in the blood, this can be a sign that there is still cancer remaining in the body. This means there’s a chance that the cancer could return.

Follow-up blood tests and imaging scans are an effective way to help catch cancer as early as possible, if it comes back.

The RaDaR test can help your care team check to see if your cancer has returned. RaDaR can find cancer months sooner than traditional tests, such as imaging.1-4

How does RaDaR work?

Cancer can behave unpredictably. When you undergo treatment to remove a tumor, the goal is to remove it all so that it doesn’t come back. Unfortunately, sometimes the surgery or other treatment is not enough. One way to detect any remaining cancer in your body after treatment is by detecting circulating tumor DNA, or ctDNA, which is shed by the tumor into your bloodstream. This is what RaDaR is designed to do, and it may help your doctor determine if you need further treatment or not.

With a simple blood test, RaDaR can detect extremely small traces of ctDNA (cancer cells; also called minimal residual disease, or MRD) with a great deal of precision and up to months sooner than traditional tests.5 RaDaR can also be used throughout the duration of your care to know how the tumor responded to curative-intent therapy and whether there is remaining ctDNA or not.

RaDaR is completely personalized to your cancer, so you and your care team can be confident about the results.

What happens with my blood sample?

There are a few steps that take place before you send in your blood sample for the RaDaR test.


First, your oncologist will send NeoGenomics a tissue sample from your tumor, either from a biopsy or from removal surgery.


Next, our lab technicians will determine the unique profile of your particular cancer, and manufacture a RaDaR panel personalized to you. This process takes about 4 weeks.


Then, during the course of your care, your oncologist can ask for blood samples to be sent to our labs to check on the status of your cancer.


Once we receive your blood sample, our technicians will test your blood sample using your personalized RaDaR panel. They will look for traces of ctDNA that may still be present in your body. This process takes about seven calendar days.


After seven calendar days, your oncologist will receive a clear, detailed report from NeoGenomics, indicating whether ctDNA (cancer cells) were detected. From there, your oncologist will be armed with information that may be used to guide the next steps in your care plan.

Our dedicated Patient Billing Team team is here to help navigate financial assistance

At NeoGenomics, our promise is to ensure the highest care for our patients. We are committed to working with patients and providers to ensure that our billing process is simple and provides access to high-quality diagnostic services.

We believe every patient should have access to the best possible care. We have a dedicated Patient Billing Team team to assist with insurance appeals, retro-authorizations, financial assistance, interest-free payment plans, prompt payment discounts and more. Both insured and uninsured patients may qualify for no-cost or reduced-cost testing through billing resource programs.


Get your RaDaR Discussion Guide and learn how to have informed discussions about where RaDaR fits into your care plan.

References: 1. Lipsyc-Sharf M, et al. J Clin Oncol. 2022;40:2408-2419. 2. Gale D, et al. Ann Oncol. 2022;33(5):500-510. 3. Flach S, et al. Accessed February 24, 2023. 4. Elliot MJ, et al. San Antonio Breast Cancer Symposium, 2022. Abstract P6-01-16. 5. Tie J, et al. Sci Transl Med. 2016;8(346):346ra92. doi:10.1126/scitranslmed.aaf6219.

We're here for you

Looking for additional information on RaDaR? Our Patient Support Team is on hand to help with any questions.

Zip Code